Aims: Ghrelin is a gastric-derived hormone that stimulates growth hormone (GH) secretion and has a multi-faceted role in the regulation of energy homeostasis, including glucose metabolism.
Although the physiologic functions of ghrelin are closely linked to the metabolic abnormalities in obesity, little is known regarding the metabolic effects of ghrelin in obese humans or in the setting of insulin resistance. This is important knowledge in determining the therapeutic potential of targeting the ghrelin system in obesity and metabolic disorders. Circulating ghrelin concentrations are lower in obese, as compared to lean, individuals 14, 15 and they are accompanied by an attenuated GH response to ghrelin administration. 3, 16 The hyperglycaemic response to exogenous ghrelin is retained in obese subjects. [16] [17] [18] Ghrelin infusion in lean subjects reduced insulin secretion and impaired glucose tolerance in response to intravenous glucose [19] [20] [21] and also worsened insulin-stimulated glucose uptake (insulin sensitivity) during hyperinsulinaemic-euglycaemic conditions. 10 The effects of ghrelin on insulin resistance in the obese have not been reported.
Roux-en-Y gastric bypass (RYGB) surgery is the most effective treatment for severe obesity and metabolic comorbidities. RYGB involves dividing the stomach to create a small gastric pouch, which is then anastomosed to the jejunum. The altered gastrointestinal anatomy and nutrient exposure after surgery produces changes in gastrointestinal hormones that regulate nutrient and energy homeostasis that is thought to contribute to the weight loss-independent improvement in glucose metabolism. Plasma ghrelin concentrations were initially reported to substantially decrease after RYGB 22 ; however, subsequent studies have provided conflicting data. 23 This discrepancy has been attributed to small study cohorts, variations in surgical technique, differences in ghrelin measurements and length of time after surgery. 23 Some data support an initial decrease in ghrelin concentrations at early postoperative time points, which rebounds later. [23] [24] [25] The purpose of this study was to perform initial studies to determine if central and peripheral responses to ghrelin were altered in obesity and changed early after RYGB, a time of caloric restriction with minimal weight loss. We examined central ghrelin effects by measuring the GH and pancreatic polypeptide (PP, a measure of vagal activity) responses to ghrelin infusion. We also assessed the peripheral effects of ghrelin by measuring hepatic and muscle insulin sensitivity with hyperinsulinaemic-euglycaemic clamps during acyl ghrelin infusion.
| MATERIALS AND METHODS

| Study participants
Obese participants who were approved for RYGB were recruited from the Vanderbilt Center for Surgical Weight Loss and lean participants with a BMI <30 kg/m 2 were recruited from the community.
This study included participants without evidence of type 1 or type 2 diabetes, liver or kidney disease, or abnormal cardiac function. Two obese subjects were withdrawn from the study because of the inability to maintain venous or arterial access during the first study visit.
Nine obese and 9 lean subjects completed the study. All study proce- 10, 11, 26 and to show differential effects in obesity. 3 The duration of infusion coincided with the time needed to reach steady state in the hyperinsulinaemic-euglycaemic clamps. The infusion order of ghrelin or saline was randomized for each study visit; participants were blinded to the order of infusion. given a meal and remained on the CRC. Participants were given a standardized meal and snack, and restricted to water after 8:00 PM.
All study procedures were repeated the second day, except with the alternate infusion (ghrelin or saline). Fat mass and fat-free mass were acquired by dual-energy x-ray absorptiometry as previously described. 27 
| Sample collection and analysis
Blood was collected in chilled ETDA tubes and immediately processed and frozen. Glucose was measured by the glucose oxidase method (YSI 2300 STAT Plus). Insulin was measured by RIA (Millipore, Billerica, Massachusetts). Acyl ghrelin was measured using a 2-site sandwich assay specific for the full-length peptide as previously characterized 28 ; AEBSF (8 mM) was added to blood and plasma was acidified (0.1N HCl 
| Calculations
| Statistical analyses
Data are expressed as mean AE SEM. Incremental area under the curve (AUC) was calculated using the trapezoidal rule. Repeated measures 2-way ANOVA was used to test for a treatment (ghrelin or saline) by group (lean or obese pre-RYGB) interaction and treatment (ghrelin or saline) by time (pre-RYGB or post-RYGB) interaction; Bonferonni post-hoc tests were used to determine the effect of ghrelin within each group or time point. Unpaired and paired Student's ttests were also used to make comparisons as appropriate; data distributions were examined and non-parametric tests were used for nonnormally distributed data. P < .05 was considered significant. Analyses were performed in GraphPad Prism version 6. Power and sample size calculations were based on published data in 8 lean subjects which demonstrated a 2.9 mg kg −1 min −1 reduction in peripheral insulin sensitivity with ghrelin infusion. 10 We estimated that a sample size of at least 9 subjects per group would allow us to detect a 1.9 mg kg −1 min −1 within-group difference in peripheral insulin sensitivity with ghrelin infusion (alpha = .05, 90% power).
3 | RESULTS
| Characteristics of study participants
Study cohorts consisted of 9 lean subjects and 9 obese subjects of similar age, and were all females without type 2 diabetes (Table 1) . At approximately 2 weeks (14 AE 3 days) after RYGB, obese participants lost 6.1 AE 0.4 kg (P ≤ .0001), amounting to a 5.4% AE 0.4% body weight loss. Approximately two-thirds of the weight loss was the result of decreased fat-free mass (Table 1) .
| Ghrelin concentrations
Acyl and total ghrelin levels during saline and ghrelin infusions within the basal period of the clamp are shown in Figure 1A ,C. Lean subjects had an endogenous, fasting acyl ghrelin concentration~60% higher than obese subjects before RYGB (79.8 AE 19.0 vs 31.7 AE 3.6 pg/mL, P < .0001). At 2 weeks after RYGB, acyl ghrelin was reduced by~50% followed the same trend, although there were differences in the comparisons that reached significance.
Others have observed that insulin infusion decreases circulating endogenous ghrelin levels. 30, 31 During the insulin infusion period on the saline day, endogenous acyl ghrelin concentrations were decreased by~40% in lean individuals (P < .0001) but not in obese individuals (P = .603; P = .0009, group × treatment interaction) or after RYGB (P = .398). There was no effect of insulin on plasma acyl ghrelin levels during ghrelin infusion (all P ≥ .678).
| Tolerability and cardiovascular effects of ghrelin infusion
The ghrelin infusion was well-tolerated by all participants. Hunger and fatigue were each reported by only 2 subjects. Heart rate and blood pressure were monitored throughout the study (Table 2) .
Ghrelin infusion did not alter heart rate in lean nor in obese pre-RYGB individuals, but caused a small but significant decrease in heart rate at 2 weeks after RYGB (−6 AE 2 bpm). Systolic blood pressure was significantly decreased in lean participants with ghrelin infusion (−9 AE 4 mm Hg), but was not altered in obese pre-RYGB and post-RYGB subjects. Neither diastolic blood pressure nor mean arterial pressure were affected by ghrelin infusion.
| Effect of ghrelin infusion on GH and PP
Ghrelin infusion stimulated GH secretion in lean, obese pre-RYGB and post-RYGB subjects (Figure 2A-C) . There was no differential effect of ghrelin infusion on GH AUC between lean and obese individuals ( Figure 2G ; P = .421 for treatment × group interaction); however, 2 lean subjects had spontaneous GH secretion during saline infusion (as previously observed 32 ) that likely affected this analysis.
When directly comparing GH AUCs from the ghrelin infusion day only, lean individuals had significantly higher GH secretion than obese individuals (P = .003). The effectiveness of ghrelin to increase GH secretion was increased after RYGB ( Figure 2G ) (P = .0002, time × treatment interaction). We also measured IGF-1, a mediator of the effects of GH and negative regulator of GH secretion. IGF-1 did not change in response to ghrelin infusion in lean subjects ( Figure S1A ,B) despite a large increase in GH (Figure 2A) . Therefore, we did not measure IGF-1 during ghrelin infusion in obese pre-RYGB and post-RYGB subjects. Obese individuals had significantly lower FIGURE 1 Acyl (A,B) and total (C,D) ghrelin levels during the basal (A,C) and insulin (B,D) periods of the hyperinsulinaemic-euglyacemic clamp procedure with saline or ghrelin infusion. Data are expressed as mean AE SEM for n = 9 per group. **P < .01, ***P < .001, and ****P ≤ .0001 for lean vs obese individuals and obese/pre-RYGB vs post-RYGB individuals fasting IGF-1 levels compared to lean individuals, with no change post-RYGB ( Figure S1C ).
Ghrelin infusion stimulated PP secretion only in obese pre-RYGB subjects ( Figure 2D-F ). There was a differential effect of ghrelin infusion on PP AUC between lean and obese individuals ( Figure 2H) (P = .015 for treatment × group interaction). The effect of ghrelin to increase PP secretion was reduced after RYGB ( Figure 2H ) (P = .021, time × treatment interaction).
| Effect of ghrelin infusion on peripheral glucose metabolism
After 2 hours of ghrelin infusion, plasma glucose levels were significantly increased in lean and obese pre-RYGB individuals, and the effect was significantly greater in obese individuals ( Table 2 ). The effect of ghrelin to increase plasma glucose was attenuated after RYGB. Ghrelin infusion did not alter HGP in the lean, obese pre-RYGB or post-RYGB individuals (Table 2 ). There was a slight effect of ghrelin to reduce hepatic insulin sensitivity in lean individuals that was not present in obese individuals, before or after RYGB ( Figure 3A ).
Ghrelin infusion decreased insulin-stimulated glucose disposal
(M value) in lean, obese pre-RYGB and post-RYGB individuals (Table 2) . However, there was no significant difference in the effect of ghrelin on the M value in lean compared to obese pre-RYGB individuals or in obese pre-RYGB compared to post-RYGB individuals.
While ghrelin did not significantly affect steady-state insulin concentrations during the clamp procedure in any of the 3 groups (Table 2) Abbreviations: bpm, beats per minute; DBP, diastolic blood pressure; FFA, free fatty acids; HGP, hepatic glucose production; M, glucose infusion rate during hyperinsulinemic euglycaemia; HR, heart rate; MAP, mean arterial pressure; mm Hg, millimeters of mercury; SBP, systolic blood pressure.
Data are expressed as mean AE SEM for n = 9 per group, except for cardiovascular measurements which are n = 8 for RYGB subjects.
*P < .05, **P < .01, ***P < .001 and ****P ≤ .0001 for saline vs ghrelin posthoc test.
the hyperglycaemic response to ghrelin infusion is present in obese individuals and appears to be greater than the response observed in lean individuals. Nonetheless, we did not detect an increase in hepatic glucose production with ghrelin infusion that could explain the observed increase in plasma glucose production, in agreement with previous reports. 10, 11 Ghrelin caused similar reductions in skeletal muscle insulin sensitivity in obese and lean individuals that was of a degree similar to that reported for a higher ghrelin infusion rate. 10, 11, 26 Tong and colleagues did not find an effect of ghrelin on insulin sensitivity in lean, healthy volunteers despite using a higher ghrelin dose 19, 21 ; however, a different methodology was used to evaluate insulin sensitivity (IV glucose tolerance test with minimal model), which may explain to this discrepancy. The mechanism(s) responsible for ghrelin-induced insulin resistance is unknown.
Although GH can cause insulin resistance and glucose intolerance, 33 the effects of ghrelin on glucose metabolism appear to be , obese pre-RYGB (B, E) and post-RYGB (C, F) subjects. Data are expressed as mean AE SEM for 7 to 9 subjects per time point. G and H, Area under the curves for GH (G) and PP (H) responses to saline and ghrelin infusions for panels A-F. Data are expressed as mean AE SEM for 9 lean subjects and 9 subjects before and after RYGB. ***P < .001 and ****P ≤ .0001 for saline vs ghrelin; # P < .05 and ### P < .001 for group × treatment or time × treatment interactions FIGURE 3 Liver and muscle insulin sensitivity in response to ghrelin infusion. A, HISI, Hepatic insulin sensitivity index. B, M/I, glucose infusion rate/plasma insulin concentrations during hyperinsulinaemic euglyacemia as a measure of peripheral (mostly muscle) insulin sensitivity. Data are expressed as mean AE SEM for 9 lean subjects and 9 subjects before and after RYGB. **P < .01 and ***P < .001 for saline vs ghrelin. #P < .05 for group × treatment interaction independent of ghrelin-induced GH secretion in humans. 11, 12, 34 Our data may support this because of the differential effects of ghrelin on GH secretion and the consistent effects on insulin sensitivity across differing metabolic states. However, we cannot completely rule out the possibility of a differential sensitivity to the peripheral actions of GH. Genetic or pharmacological blockade of the GHSR-1a in rodents results in improved insulin sensitivity, suggesting a receptor-mediated mechanism. 35, 36 Given that both insulin-sensitive lean individuals and insulin-resistant obese individuals had similar reductions in insulinstimulated glucose uptake, it is unlikely that ghrelin infusion directly interferes with insulin signaling. This is in agreement with the lack of an effect of ghrelin infusion on muscle insulin signaling pathways in humans. 11, 37 Local administration of ghrelin to the muscle did not alter glucose uptake, indicating an indirect, systemic effect of ghrelin on muscle insulin sensitivity, 37, 38 which warrants further investigation.
Ghrelin was discovered as a gastric peptide that is a direct, endogenous stimulator of GH secretion, which plays a role in nutrient metabolism and body composition. Consistent with previously reported findings, data from our study suggest that the central effects of peripherally-secreted ghrelin may be exerted directly, 6 probably on the hypothalamus, [39] [40] [41] or mediated via the vagus nerve. 4, 7, 8, 42, 43 Several lines of evidence support a primarily hypothalamic effect of ghrelin on GH secretion. 41 For example, ghrelin receptors are present on GHRH neurons, which are stimulated by ghrelin. 39 Additionally, hypothalamic-pituitary disconnection in humans blunts the GH response to ghrelin, suggesting a hypothalamic site of action of ghrelin. 40 However, we cannot discount that the ghrelin-induced GH secretion in our study results from the direct effects of ghrelin on the pituitary. We observed a blunted GH response to ghrelin in obese individuals, consistent with 2 previous reports. 3, 16 At 2 weeks after RYGB surgery, the responsiveness of GH to ghrelin is nearly normalized. The differential effects of ghrelin on GH do not appear to be related to IGF-1, as it did not change in response to acute ghrelin infusion despite increased GH, consistent with previous reports. 26, 44 Fasting IGF-1was not altered at 2 weeks after RYGB; however, the literature is inconsistent in this regard. [45] [46] [47] While the exact mechanisms of the observed improvement in the central effect of ghrelin after RYGB are unclear, they are probably related to the postoperative caloric restriction concurrent with a 5% weight loss. A body of literature concerning rodents describes a hypothalamic ghrelin resistance in the obese state that is reversed by diet-induced weight loss. 48 Another potential contributing factor could be related to thẽ 50% reduction in plasma ghrelin after RYGB. Lean subjects with long-term total gastrectomy had a~50% reduction in ghrelin levels and increased ghrelin-induced GH secretion compared to matched subjects with an intact stomach. 49 These data raise the possibility that the reduction in ghrelin levels observed after RYGB could lead to hypersensitization of the hypothalamus and contribute to the improvement in ghrelin-induced GH secretion after.
We indirectly assessed the effect of ghrelin infusion on vagal signaling by measuring PP secretion, which is largely under vagal control. 50 Ghrelin infusion did not stimulate PP secretion in lean subjects. This is consistent with another report showing that a constant ghrelin infusion did not alter PP secretion, 51 but differs from another study wherein a bolus injection of ghrelin caused PP secretion in lean subjects. 52 The vagal hyper-responsiveness to ghrelin in obese subjects was attenuated following RYGB. While care is taken during the RYGB procedure to preserve the vagal trunks, it is conceivable that nerve branches are compromised during creation of the gastric pouch, causing vagal dysfunction. 53 In rodents, blockade of vagal signaling attenuated ghrelin-induced GH secretion and feeding, 7, 8 although the latter effect was not observed in one study. 42 Conversely, ghrelin infusion in human subjects with previous vagotomy retain the GH-stimulating effects of ghrelin 9, 43 but no longer respond to the feeding effect of ghrelin. 4, 9 Taken together, studies in humans suggest that the effect of ghrelin in increasing GH secretion is mediated primarily by the hypothalamus, and it is probable that the increased vagal activation observed in obese individuals, which is reversed with RYGB, is not related to GH secretion, but rather to feeding behaviors. Interestingly, one study reported that obese subjects had increased sensitivity to the appetite-stimulating effects of ghrelin compared to lean individuals. 3 Further work is clearly necessary to elucidate the effects of obesity and RYGB on the central responses to ghrelin.
It is important to note that our study has some limitations. This was a single-blind study in a small, homogenous (females without diabetes) cohort, and additional studies are needed, with larger cohorts, to determine if the results are applicable to other populations. As we were interested in the potential role of ghrelin in the immediate metabolic improvements after surgery, future studies should explore ghrelin responsiveness in the long-term after RYGB. Our findings were observed with acute elevations of plasma ghrelin to supraphysiologic levels and, therefore, such findings cannot be extrapolated to account for metabolic effects that might occur with chronic changes in ghrelin levels. The hyperinsulinaemic-euglycaemic clamp allows direct evaluation of the effect of ghrelin on tissue insulin sensitivity, and future studies should explore the potential contribution of neurohormonal signals, such as GLP-1 51, 54 , from the gastrointestinal tract or the known effect of ghrelin to reduce glucose-stimulated insulin secretion. 20, 21, 51 In summary, this is the first study to examine the metabolic effects of exogenous ghrelin administration in Class III obese subjects before and after RYGB. The peripheral effects of ghrelin were not altered in obese individuals or changed after RYGB. While our data do not suggest that changes in ghrelin after RYGB affect peripheral insulin sensitivity, additional studies, as outlined above, are necessary to fully characterize the involvement of ghrelin in the beneficial peripheral metabolic effects of RYGB. Conversely, we observed altered central effects of ghrelin in obese individuals that were restored to that of lean individuals at 2 weeks after RYGB. These data indicate that different pathways may regulate the central and peripheral metabolic effects of ghrelin and that the central metabolic effects of ghrelin are sensitive to metabolic status.
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